Conformational analysis |
PAMAM G2 to G6 [87] |
Insight II |
Insight II ƚ CHARMM ƚ
|
CVFF CHARMM |
Structural features at different pH and generations |
PAMAM G5 [88] |
NA* |
MPsim |
DREIDING |
Effect of pH to study the water dynamics on dendrimers |
PAMAM G50% and 90% acetylated [89] |
Insight II |
AMBER8 ƚ
|
GAFF |
Effect of acetylation on structural features |
Glycosylated PAMAM G3.5 [90] |
XPLOR |
Desmond §
|
OPLS_2005 |
Effect of glycosylation on structural features |
Triazine G3 and G5 with DOTA terminals [91] |
AMBER 11 |
AMBER 11 ƚ
|
GAFF and parm99 |
Location of DOTA groups complexed with Gd ions |
PEgylated PAMAM G3 to G5 [92] |
NA * |
GROMACS §
|
MARTINI |
Effect of PEGylation on the structure and interparticle interaction |
Pegylated triazine dendrimers linked with paclitaxel [72] |
Material Studio 5 |
AMBER 11 ƚ
|
parm99 |
Effect of PEGylation on availability of linkers |
Carboxylic modified PAMAM G5 with gold, fluorescein isothiocyanate (FI) and folic acid (FA) [93] |
Insight II |
Insight II ƚ
|
CVFF |
Conformation and location of FI and FA |
PAMAM G5 with amine, carboxyl and acetamide groups linked to fluorescein and folic acid [80] |
Insight II |
Insight II ƚ
|
CVFF |
Location of folic acid and its availability |
PAMAM G5 with methotrexate [29] |
CHARMM |
CHARMM ƚ
|
CHARMM |
Location of MTX when directly linked or with a spacer |
Poly(l-lysine) and Poly(amide) G4 dendrimers [94] |
Starmaker (Silico) |
NAMD §
|
OPLS-AA |
Comparison of dendrimer architectures in solution |
Dendrimer-small molecule interactions |
PAMAM G5 with different terminal
81] |
Insight II |
Insight II ƚ
|
CVFF |
Influence of terminal groups on the complexation |
PAMAM G4 + polyphenols [55] |
ChemOffice Ultra 6.0 |
HyperChem Pro 7.0 ƚ
|
MM+ |
Free binding energies |
PAMAM G3 + nicotinic acid, nicotinate and 3-pyridiniumcarboxylate [95] |
HyperChem |
NAMD §
|
CHARMM27 |
Free energy of binding and the effect of pH variation on binding |
Peptide dendrimers + hydroxypyrene trisulfonate butyrate ester [38] |
CORINA |
GROMACS §
|
GROMOS-96 43a1 |
Conformation and docking site location |
PAMAM G5-Folic acid + Morphine and Tramadol [96] |
ICM |
NAMD §
|
CHARMM 27; ParamChem |
Different pHs; Binding mechanism elucidadtion; Location of folic acid |
PAMAM G5 + salicylic acid, L-alanine, phenylbutazone, primidone [97] |
DBT/AMBER |
AMBER9 ƚ
|
GAFF |
Effect of pH on interaction and relation with drug release |
Poly(l-lysine) G4 dendrimer + doxorubicin [83] |
ChemBioOffice |
Desmond §
|
OPLS-AA |
Complex formation |
Dendrimer-nucleic acid interaction |
Triazine G2dendrimers + siRNA or DNA [98] |
AMBER 10 |
AMBER 10 ƚ
|
Parm99 |
Binding mechanism and energy contributions |
PAMAM ssDNA [49] |
AMBER 7 |
AMBER 7 ƚ
|
AMBER 95 (DNA) DREIDING (dendrimer) |
Binding interaction and energy contributions |
PAMAM G3 DNA [75] |
NA * |
NAMD §
|
CHARMM 27 |
Complexation mechanism |
PAMAM G0 and G1 + siRNA [43] |
Material Studio 5 |
AMBER9 ƚ
|
Ff99 FF for RNA GAFF for dendrimers |
Effects of pH on the complexation |
PAMAM G7 + siRNA [99] |
Material Studio 5 |
AMBER10 ƚ
|
GAFF (non-standard residues); parm99 |
Complex interaction |
Dendrimer-protein interaction |
Glycosylated PAMAM G3.5 + MD-2 protein [52] |
XPLOR |
Desmond §
|
OPLS_2005 |
Docking and interaction between active and non-active forms |
PAMAM G4 Albumin [47] |
NA * |
NA * |
DREIDING |
Contact points between dendrimer-albumin at physiological pH |
PAMAM G0 with guanidinium terminal groups α-chymotrypsinogen A [73] |
NA * |
NAMD §
|
CHARMM 27 |
Site of interaction with the protein and effect of salt types |
Dendrimer-lipid bilayer interaction |
Acetylated and non-acetylated PAMAM G5 and G7 + DMPC [53] |
Insight II |
GROMACS §
|
MARTINI and adapted MARTINI |
Effect of size, charge and concentration on dendrimer-membrane interaction |
PAMAM G3 and G5 with different acetylation levels + DPPC [60] |
Insight II |
GROMACS §
|
MARTINI |
Effect of size, charge and lipid phase on dendrimer-membrane interaction |
PAMAM G3 with amine, acetyl and carboxyl terminals + DMPC [74] |
CHARMM |
CHARMM ƚ
|
CHARMM27 (lipid) and CHARMM 22 (dendrimer) |
Effect of terminal groups and lipid phase |